§ 13F · FUND PROFILE
Versant Venture Management, LLC.
Institutional filer · behavioral pattern: Other. Summary pending.
AUM · $212M (13F)Positions · 9Turnover · — · Q1Filed · May 5, 2026
CONCENTRATION
—
Top 10 holdings
NEW BUYS
0
+$27M deployed
EXITS
0
No exits
SECTOR SHIFT
—
No prior quarter data
3YR HIT RATE
—
Top-5 overlap
§ 01 · TOP HOLDINGS
The book · Q1 2026
FILED MAY 5, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q1 |
|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics, Inc. | 3.18M | $52M | 37.0% | −27% |
| 2 | IPSC | Century Therapeutics, Inc. | 12.17M | $27M | 19.4% | NEW |
| 3 | LENZ | Lenz Therapeutics, Inc. | 2.66M | $24M | 17.2% | ±0% |
| 4 | JBIO | Jade Biosciences, Inc. | 1.53M | $21M | 15.2% | ±0% |
| 5 | CTNM | Contineum Therapeutics, Inc. | 543K | $7M | 5.0% | ±0% |
| 6 | CRSP | CRISPR Therapeutics AG | 149K | $7M | 5.0% | ±0% |
| 7 | SKYE | Skye Bioscience, Inc. | 2.01M | $1M | 0.9% | ±0% |
| 8 | OVASUSD | Tempest Therapeutics, Inc. | 270K | $442K | 0.3% | ±0% |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE VERSANT SIGNAL
AC read
Versant Venture Management, LLC is a Other fund managing $212 million in assets. The fund runs a focused portfolio of just 9 positions.
Read the full dossier →§ 04 · FILING HISTORY
Q-by-Q deltas
2 FILINGS
Q1 2026
Steady book
+0 buys · −0 exits · 0 changed
Q4 2025
Steady book
+0 buys · −0 exits · 0 changed
Q3 2025
Steady book
+0 buys · −0 exits · 0 changed
Q2 2025
Steady book
+0 buys · −0 exits · 0 changed